Latest Breaking News On - Ambrish mithal - Page 6 : comparemela.com

From Elon Musk to several Hollywood celebrities, the weight loss wonder drug, semaglutide, is taking the world by storm. What was an unintended consequence of a diabetes control med, the emergence of significant weight loss has raised the expectation of the wonder drug becoming a $100 bn opportunity by 2030. While the drug’s innovator Novo Nordisk launched its oral version in India last year, Dr. Reddys Laboratories has now got approval to carry out bioequivalence studies of injectable semaglutide. So, what does this mean for India that has a huge disease burden of diabetes and obesity? Is the hype around the drug all worth it? Are there any side effects? Is it affordable? And who should be taking it? Host Kiran Somvanshi tries to understand from Dr. Ambrish Mithal, Chairman & Head - Endocrinology & Diabetes - Max Healthcare, and Nithya Balasubramanian, Director - AB Bernstein. Listen to the latest episode of The Morning Brief podcast!Disclaimer: The analyst interviewed has a

United statesNithya balasubramanianAmbrish mithalKiran somvanshiNovo nordiskFrom elon muskReddys laboratoriesHost kiran somvanshiMorning briefLupin creditsOzempic commercialJimmy kimmel liveWonder drugWeight loss wonder drugWeight lossDiabetes control med